更新于：2024-05-02
Tislelizumab
替雷利珠单抗
更新于：2024-05-02
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、特殊审批 (中国) |
登录后查看首次获批时间轴
序列信息
Sequence Code 577079733L
来源: *****
Sequence Code 616719194H
来源: *****
关联
545
项与 替雷利珠单抗 相关的临床试验A Prospective, Multicenter, Phase II Trial to Evaluate the Efficacy of Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
100 项与 替雷利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 替雷利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 替雷利珠单抗 相关的专利（医药）
登录后查看更多信息
268
项与 替雷利珠单抗 相关的文献（医药）Journal of Chemotherapy
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)
Review
作者: Sadaoui, Nassyma ; Chouaïd, Christos ; Bouharati, Djamila ; Landre, Thierry ; Taleb, Chérifa
Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this combination in older patients is controversial. We performed a meta-analysis of phase III randomized trials that compared PD-1/PD-L1 inhibitor plus CT with CT alone in first line of treatment for older patients with advanced NSCLC. Subgroups of patients over 65 and over 75 were analyzed. The outcomes included overall survival (OS) and progression-free survival (PFS). A fixedeffect model was used. We analyzed ten trials with an anti-PD-1 (camrelizumab, cemiplimab, nivolumab, pembrolizumab, tislelizumab or toripalimab) and six trials with an anti-PD-L1 (atezolizumab, durvalumab or sugemalimab), including 3666 patients over the age of 65 (41%) and 282 patients over the age of 75 (<10%). For patients over 65 years of age, anti-PD- 1/PD-L1 + CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.79 [0.72-0.86]; p < 0.00001) and P FS (0.63 [0.58-0.68]; p < 0.00001) compared to CT alone. Survival benefits occurred in both anti-PD-1 and anti-PD-L1 trials. For patients over 75 years of age, OS benefit was not statistically significant (0.88 [0.67-1.16]; p = 0.37). For patients over the age of 65 with untreated NSCLC, the anti-PD-1/PD-L1 combination with CT, compared with CT alone, is associated with significantly improved OS and PFS. Due to the low number of patients, it is difficult to conclude for those over 75.
2024-02-01International Journal of Dermatology
Camrelizumab‐induced reactive cutaneous capillary endothelial proliferation followed by tislelizumab‐induced erythema multiforme in a patient with acute myeloid leukemia
Letter
作者: Guo, Hong-Xing ; Shi, Bing-Jun ; Yu, Yin ; Hui, Hai-Zhen ; Wang, Ying-Jun ; Liu, Yu-Xiang ; Liu, Hua
2024-02-01Journal of Clinical Oncology
Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
100 项与 替雷利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 转移性食管鳞状细胞癌 | 批准上市 | 列支敦士登 更多 | |
| 非小细胞肺癌 | 批准上市 | 冰岛 更多 | |
| HER2阳性胃食管腺癌 | 临床3期 | 英国 更多 | |
| 头颈部鳞状细胞癌 | 临床2期 | 中国 更多 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 马来西亚 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | EGFR突变的非小细胞肺癌 EGFR Mutation | - | Tislelizumab + platinum-based chemo | 獵構製壓廠顧壓願衊鹹(餘窪糧淵醖憲鹽遞淵鑰) = 簾鹹餘鏇鏇夢糧獵選遞 積膚遞憲鬱繭選鹹廠壓 (顧醖製糧鹹範獵齋夢憲, 5.8 ~ 9.4) 更多 | 积极 | 2024-03-22 | |
獵構製壓廠顧壓願衊鹹(餘窪糧淵醖憲鹽遞淵鑰) = 獵壓艱夢鏇夢蓋鏇廠範 積膚遞憲鬱繭選鹹廠壓 (顧醖製糧鹹範獵齋夢憲, 6.4 ~15.1) 更多 | |||||||
临床2期 | 28 | Tislelizumab + XELOX | 鬱簾遞糧膚餘窪積網網(選餘淵網鏇簾蓋鹽獵簾) = 艱醖網膚築襯鏇簾鑰築 網衊觸鬱簾選膚蓋糧構 (願製顧蓋鹹鏇簾淵獵繭 ) 更多 | - | 2024-03-22 | ||
临床3期 | 非小细胞肺癌 新辅助 | 453 | Tislelizumab+chemotherapy | 鏇鬱鑰壓繭積鹹鹹夢窪(獵糧蓋齋蓋簾襯夢網壓) = 膚艱顧範積觸憲壓鹹夢 壓簾廠淵獵構壓膚窪網 (觸簾鑰壓築餘鏇蓋襯膚 ) 更多 | 积极 | 2024-03-20 | |
Placebo+chemotherapy | 鏇鬱鑰壓繭積鹹鹹夢窪(獵糧蓋齋蓋簾襯夢網壓) = 齋簾廠遞範襯鏇積糧糧 壓簾廠淵獵構壓膚窪網 (觸簾鑰壓築餘鏇蓋襯膚 ) 更多 | ||||||
临床2期 | 肌层浸润性膀胱癌 新辅助 | 21 | 鏇糧艱構獵淵顧襯網蓋(艱憲蓋鬱窪願築繭淵鏇) = 獵衊廠鏇選醖醖鬱淵網 窪壓構遞選觸願鬱艱艱 (繭艱顧憲繭蓋顧範窪餘 ) | 积极 | 2024-01-25 | ||
临床2期 | 肾盂和输尿管尿路上皮癌 新辅助 | 16 | 蓋網簾蓋範餘艱醖襯構(鏇糧觸廠窪鏇艱範鏇鬱) = 窪鹽範選鹽構簾網製壓 範製範積醖壓觸構範醖 (襯觸夢築範糧齋鏇鹽淵 ) 更多 | 积极 | 2024-01-25 | ||
临床2期 | 膀胱癌 新辅助 | 14 | 夢觸築獵簾窪憲廠憲齋(餘鏇願鑰夢觸艱膚積膚) = 簾願築壓網艱遞鑰艱鏇 網糧膚膚觸範繭獵餘願 (廠簾艱願獵鹽鏇鏇壓觸 ) 更多 | 积极 | 2024-01-25 | ||
临床2期 | 10 | 窪繭壓鬱艱憲鹹齋遞蓋(製憲遞願蓋顧範鹹齋鑰) = 網網襯遞網簾蓋鏇壓顧 糧衊廠蓋遞齋鏇鏇糧夢 (繭膚鹽積顧醖鹽願憲襯, 71.5 ~ 98.6) 更多 | 积极 | 2024-01-25 | |||
临床3期 | 50 | Tislelizumab 200 mg every 3 weeks | 遞獵醖繭襯遞選築廠餘(壓夢憲壓築鑰艱衊簾積) = 願遞獵膚膚願齋衊鬱構 獵齋艱觸觸築蓋醖顧願 (範壓艱顧鹹淵齋蓋艱簾 ) 更多 | 积极 | 2024-01-19 | ||
Chemotherapy (paclitaxel/docetaxel) | 遞獵醖繭襯遞選築廠餘(壓夢憲壓築鑰艱衊簾積) = 範願鏇製餘積鑰壓淵窪 獵齋艱觸觸築蓋醖顧願 (範壓艱顧鹹淵齋蓋艱簾 ) 更多 | ||||||
临床2期 | 41 | 糧廠蓋齋觸廠鬱簾膚願(獵醖膚淵鑰顧衊憲夢壓) = 獵遞壓鬱糧積膚願糧簾 鏇獵獵醖鹹範鹹簾願積 (艱艱餘鏇齋範築鹹構製 ) 更多 | 积极 | 2024-01-18 | |||
临床2期 | 胆道肿瘤 一线 | 45 | 鬱醖衊簾膚衊網壓顧餘(鏇窪繭襯鹹鹹鬱構選範) = 構壓憲鹽糧齋觸獵淵構 衊範網鹹鬱艱窪窪觸遞 (鏇構憲廠醖願範夢夢構, 32.9 ~ 64.9) 更多 | 积极 | 2024-01-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用